Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Walter Reed Army Medical Center

Status: Completed

Conditions: Healthy

Treatments: Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Study type: Observational

Funder types: Other U.S. Federal agency

Identifiers

NCT00413751

WRAMC WU #03-23004

Details and patient eligibility

About

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion criteria

• Patients not meeting above stated age criteria
• Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
• History of serious ocular, neurological, cardiovascular disease
• History of severe systemic disease
• History of arrhythmias or high blood pressure
• Patients currently taking any type of ocular or systemic medications except multivitamins.
• Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.